NOW CLOSED-Public Consultation Notice

Draft: Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

Proposed for submission to the NHMRC for approval under section 14A of the National Health and Medical Research Council Act 1992.

The University of Sydney, NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People and Bruyère Research Institute/Deprescribing Guidelines in the Elderly Project has prepared a draft guideline on deprescribing cholinesterase inhibitors and/or memantine in people with dementia.

Appropriate use of cholinesterase inhibitors and memantine involves both prescribing these medications to individuals who are likely to benefit, and deprescribing (withdrawing) them for individuals where the risks outweigh the benefits. The purpose of this guideline is to assist healthcare professionals to determine when it might be suitable to trial withdrawal of these medications for an individual and to guide how to conduct withdrawal.